jRCT2031260062招募中不适用
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients with Severe Alopecia Areata with an Open-Label Extension Period (THRIVE-AAJP) (THRIVE-AAJP)
未提供0 个研究点目标入组 78 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 65age old under（—）
- 性别
- All
入选标准
- •Written informed consent has been obtained.
- •Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.
- •Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.
- •SALT score of 50 or more at both Screening and Baseline.
排除标准
- •Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.
- •Treatment with biologics within 6 months prior to Screening.
- •Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.
- •History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.
- •Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.
研究者
相似试验
尚未招募
不适用
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialCardiovascular DiseasejRCT2051250217406
招募中
1 期
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain2025-523737-26-00Centrexion Therapeutics Corp.20
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX3042024-514744-91-00Betagenon AB, Betagenon AB40
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy ParticipantsSchizophrenia2025-521914-25-00Clexio Biosciences Ltd.110
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy SubjectsPulmonary fibrosis2023-504426-19-00Gat Therapeutics S.L.52